We expect investors to focus on Vaxart, Inc.’s (VXRT - Free Report) development plans for its oral coronavirus vaccine candidates when it reports first-quarter 2020 earnings results.
Shares of Vaxart have skyrocketed 850.1% so far this year against the industry’s decline of 9.4%.
The stock price has been appreciating of late owing to the company’s recent progress in making efforts to fight the COVID–19 pandemic and develop a vaccine for the same.
Vaxart’s portfolio is currently devoid of any approved product. As a result, the company only generates revenues from royalty sales. Earlier this week, Vaxart announced that itwill receive $2.8 million in royalty revenues for the first quarter.
Recent Developments
Vaxart is looking to develop a vaccine candidate that can generate mucosal immune responses in addition to serum antibody responses, which are potentially significant for protection against the deadly COVID-19 infection. In April 2020, Vaxart announced positive data from pre-clinical studies on its oral vaccine candidates against SARS CoV-2, the virus that causes COVID-19.
The study and development activities conducted in the March quarter in relation to the oral vaccine candidates are likely to have escalated the company’s operating expense in the period.
Notably, Vaxart has a manufacturing agreement with Emergent BioSolutions (EBS - Free Report) wherein the latter will produce the clinical material for the company’s experimental oral vaccine candidates against COVID-19.
Emergent plans to produce bulk cGMP vaccine to help Vaxart begin a phase I clinical study in the second half of 2020.
Vaxart, Inc. Price and EPS Surprise
Zacks Rank & Other Stocks to Consider
Vaxart currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the biotech sector include Adamis Pharmaceuticals Corporation and Avenue Therapeutics, Inc. (ATXI - Free Report) , both sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Adamis Pharmaceuticals’ loss per share estimates have been narrowed 10.5% for 2020 and 8.3% for 2021 over the past 60 days.
Avenue Therapeutics’ loss per share estimates have been narrowed 28.6% for 2020 and 26% for 2021 over the past 60 days.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
We expect investors to focus on Vaxart, Inc.’s (VXRT - Free Report) development plans for its oral coronavirus vaccine candidates when it reports first-quarter 2020 earnings results.
Shares of Vaxart have skyrocketed 850.1% so far this year against the industry’s decline of 9.4%.
The stock price has been appreciating of late owing to the company’s recent progress in making efforts to fight the COVID–19 pandemic and develop a vaccine for the same.
Vaxart’s portfolio is currently devoid of any approved product. As a result, the company only generates revenues from royalty sales. Earlier this week, Vaxart announced that itwill receive $2.8 million in royalty revenues for the first quarter.
Recent Developments
Vaxart is looking to develop a vaccine candidate that can generate mucosal immune responses in addition to serum antibody responses, which are potentially significant for protection against the deadly COVID-19 infection. In April 2020, Vaxart announced positive data from pre-clinical studies on its oral vaccine candidates against SARS CoV-2, the virus that causes COVID-19.
The study and development activities conducted in the March quarter in relation to the oral vaccine candidates are likely to have escalated the company’s operating expense in the period.
Notably, Vaxart has a manufacturing agreement with Emergent BioSolutions (EBS - Free Report) wherein the latter will produce the clinical material for the company’s experimental oral vaccine candidates against COVID-19.
Emergent plans to produce bulk cGMP vaccine to help Vaxart begin a phase I clinical study in the second half of 2020.
Vaxart, Inc. Price and EPS Surprise
Zacks Rank & Other Stocks to Consider
Vaxart currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the biotech sector include Adamis Pharmaceuticals Corporation and Avenue Therapeutics, Inc. (ATXI - Free Report) , both sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Adamis Pharmaceuticals’ loss per share estimates have been narrowed 10.5% for 2020 and 8.3% for 2021 over the past 60 days.
Avenue Therapeutics’ loss per share estimates have been narrowed 28.6% for 2020 and 26% for 2021 over the past 60 days.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on EBS - FREE
Get the latest research report on ATXI - FREE
Get the latest research report on VXRT - FREE